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Childhood trauma is among the most potent contributing risk factors for depression and is associated 
with poor treatment response. Hypothalamic-pituitary-adrenal (HPA) axis abnormalities have been 
linked to both childhood trauma and depression, but the underlying mechanisms are poorly 
understood. The present study aimed to investigate the link between childhood trauma, HPA axis 
activity and antidepressant response in patients with depression. As part of the Wellcome Trust 
NIMA consortium, 163 depressed patients and 55 healthy volunteers were included in this study. 
Adult patients meeting Structured Clinical Interview for Diagnostic and Statistical Manual Version-
5 criteria for major depression were categorised into subgroups of treatment responder (n=42), 
treatment non-responder (n=80) and untreated depressed (n=41) based on current depressive 
symptom severity measured by the 17-item Hamilton Rating Scale for Depression and exposure to 
antidepressant medications established by Antidepressant Treatment Response Questionnaire. 
Childhood Trauma Questionnaire was obtained. Baseline serum C-reactive protein was measured 
using turbidimetric detection. Salivary cortisol was analyzed at multiple time points during the day 
using the ELISA technique. Glucocorticoid resistance was defined as the coexistence of 
hypercortisolemia and inflammation. Our results show that treatment non-responder patients had 
higher exposure to childhood trauma than responders. No specific HPA axis abnormalities were 
found in treatment non-responder depressed patients. Untreated depressed showed increased diurnal 
cortisol levels compared with patients on antidepressant medication, and higher prevalence of 
glucocorticoid resistance than medicated patients and controls. The severity of childhood trauma 
was associated with increased diurnal cortisol levels only in individuals with glucocorticoid 
resistance. Therefore, our findings suggest that the severity of childhood trauma experience 
contributes to a lack of response to antidepressant treatment. The effects of childhood trauma on 





suggest glucocorticoid resistance as a target for the development of personalized treatment for a 
subgroup of depressed patients with a history of childhood trauma rather than for all patients with 




• The severity of childhood trauma experience contributes to lack of response to antidepressant 
treatment. 
• Untreated depressed patients show increased diurnal cortisol levels compared with those on 
antidepressant medication both treatment responder and non-responder patients. 
• The severity of childhood trauma contributes to increased HPA axis activity and higher cortisol 
production specifically in depressed patients who present glucocorticoid resistance.  
• Glucocorticoid resistance may be a novel target for development of personalised treatment for 
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1.  INTRODUCTION 
Major depressive disorder (MDD) is a debilitating condition and the most common psychiatric 
disorder with more than 300 million people affected worldwide according to the World Health 
Organisation. Although there are effective antidepressants available, more than one third of 
depressed patients do not respond to conventional treatments (Cleare et al., 2015, Ferrari et al., 
2013). Ongoing studies aim to improve our understanding of the biological mechanisms underlying 
the causality, development and pathogenesis of depression in order to develop new, more successful 
and personalized treatment strategies. With growing advances in psychoneuroimmunology 
research, extensive evidence suggests the importance of abnormal brain-endocrine-immune 
interaction and dysregulated neuroendocrine and neuroimmune response in the pathogenesis of 
depression (Miller and Raison, 2016). As shown by the findings from several large population 
samples and clinical meta-analyses, a significant proportion of depressed patients exhibit 
hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis thus increased secretion of the 
stress hormone cortisol as well as elevated levels of inflammatory biomarkers (Haapakoski et al., 
2015, Howren et al., 2009, Perrin et al., 2019, Valkanova et al., 2013, Zunszain et al., 2011). It has 
been suggested that such disturbances are due to the dysfunction of glucocorticoid receptors (GR), 
and therefore an impairment in cortisol to mediate HPA axis negative feedback and regulate its own 
production, and to promote anti-inflammatory response. Indeed, attenuated glucocorticoid 
responsiveness, so called glucocorticoid resistance, has been consistently observed in MDD patients 
presenting coexistence of hypercortisolemia and inflammation (Pariante, 2017, Perrin et al., 2019, 
Stewart et al., 2009). 
Early-life traumatic experiences including childhood physical, sexual and emotional abuse and/or 
neglect are among the most potent contributing risk factors for increased diathesis for major 





been linked to increased inflammation (Baldwin et al., 2018, Baumeister et al., 2016, Danese et al., 
2008) and HPA axis abnormalities such as a dysregulation of the glucocorticoid-mediated negative 
feedback and an increased cortisol reactivity in adulthood (Harkness et al., 2011, Lu et al., 2016). 
These neuroendocrine and neuroimmune alterations secondary to childhood traumatic experiences 
significantly increase vulnerability to the lifetime stress reactivity and subsequent risk for the onset 
of depressive episodes (Heim et al., 2008, Nemeroff and Binder, 2014).  
The heterogeneous nature of MDD with multifactorial aetiological and pathophysiological 
mechanisms involved, makes treatment more challenging. To date, relatively few investigations 
have been trying to address this issue and proposing predictors of treatment response in depression. 
Childhood trauma and maltreatment has been previously associated with poor treatment response 
to antidepressant pharmacotherapies (Kaplan and Klinetob, 2000, Nanni et al., 2012, Williams et 
al., 2016). The findings supporting the association between HPA axis hyperactivity and lack of 
response to treatment in depression are less consistent. While some studies reveal that treatment 
non-responder depression is associated with hypercortisolemia and elevated inflammation in the 
presence of glucocorticoid resistance (Carvalho et al., 2010, Carvalho et al., 2008) and that 
depressed patients with higher inflammation are less responsive to standard antidepressant 
treatments (Carvalho et al., 2013, Kopschina Feltes et al., 2017); a recent meta-analysis does not 
support hyperactivation of HPA axis as a predictor for antidepressant treatment response (Fischer 
et al., 2017). No previous study has investigated in the same sample of patients the association 
between childhood trauma and HPA axis with antidepressant treatment response. 
Considering the costs and challenges for patients and society associated with treatment-resistance 
in depression, it is important to identify specific and reliable biomarkers predictive of antidepressant 
efficacy as well as to distinguish those subgroups of depressed patients exhibiting physiological 





successful clinical treatment of depression. Therefore, the present study aims to investigate 1) 
whether experience of childhood trauma is associated with lack of response to antidepressant 
treatment, 2) whether abnormalities in HPA axis activity (assessed as diurnal cortisol, cortisol 
awakening response, and glucocorticoid resistance) are associated with lack of response to 
antidepressant treatment, and 3) whether the experience of childhood trauma is associated with 
specific abnormalities in HPA axis activity in patients with depression. 
2. MATERIALS AND METHODS 
2.1  Subjects 
The current cross-sectional study was conducted as part of the BIODEP (BIOmarkers in 
DEPression) Wellcome Trust Neuroinflammation Consortium, NIMA (Neuroimmunology of Mood 
Disorders and Alzheimer’s disease), an observational non-interventional study (Chamberlain et al., 
2019). Volunteers aged 25-50 years were recruited by a network of clinical research centres in the 
UK including Brighton, Cambridge, Glasgow, King’s College London and Oxford. The study 
participants consisted of patients with a current diagnosis of MDD according to Diagnostic and 
Statistical Manual Version 5 (DSM-5) (American Psychiatric Association, 2013) recruited from 
mental health and primary national health services as well as healthy adults. Patients were 
categorised by monoaminergic antidepressant (MA) exposure and therapeutic response at the time 
of the assessment. Healthy controls were sampled to match the patient group for age and sex. The 
study was approved by Research Ethics Committee (National Research Ethics Service East of 
England, Cambridge Central, UK) and conducted according to the Declaration of Helsinki. Written 
informed consent was obtained from all participants prior to performing any study related activity 





2.2 Clinical Measures 
Diagnosis of MDD and other psychiatric disorders were ascertained by Structured Clinical 
Interview for DSM-5 (Spitzer et al., 1996). The severity of depressive symptoms was assessed using 
17-item Hamilton Rating Scale for Depression (HAM-D17) (Hamilton, 1960). The exposure to 
antidepressant medications was established by Antidepressant Treatment Response Questionnaire 
(Desseilles et al., 2011). Patients were categorised into three subgroups: treatment responder 
patients who were not depressed (HAM-D<7) after at least 6 weeks of treatment with a 
monoaminergic antidepressant (DEP-MA+); treatment non-responder depressed patients who were 
depressed (HAM-D>13) after at least 6 weeks of treatment with one or more monoaminergic 
antidepressants (DEP+MA+); and untreated depressed patients who were depressed (HAM-D>17) 
but had not been treated with monoaminergic antidepressants in the previous 6 months (DEP+MA-
). Healthy volunteers had no history of depression requiring treatment with either monoaminergic 
antidepressants or other clinical interventions including psychotherapy (DEP-MA-).  
Exclusion criteria were applied for participants with life time bipolar or non-affective psychotic 
disorder, sufferers from a medical condition associated with systemic and/or CNS inflammation 
(such as immunological disorders, cardiovascular disorders, malignancies, recent or current 
infection confirmed by screening interview and further through the results of the cell blood count, 
brain disorders) and those with concurrent use of any medication likely to compromise the 
interpretation of immunological data (such as use of corticosteroids, anti-histamines and anti-
inflammatory drugs), current substance use disorders for the last 6 months, participants in clinical 
trial of an investigational drug within the last 12 months, breast feeding or pregnant women. 
Following a semi structured clinical interview, demographic characteristics of the participants were 
documented. Height and weight were measured for body mass index (BMI) calculation. Participants 





to measure the severity of different types of childhood trauma including Emotional Abuse, 
Emotional Neglect, Physical Abuse, Physical Neglect and Sexual Abuse (Bernstein et al., 1994). 
The Beck Depression Inventory II (BDI-II) (Beck et al., 1996) was also completed and followed by 
collection of fasting peripheral venous blood between 8:00-10:00am. Participants were then issued 
with the materials and instruction for collecting the saliva samples.  
2.3 Peripheral C-reactive Protein Measurements 
The nonspecific acute phase reactant, hsCRP was measured as the most reliable biomarker of on-
going inflammation implicated in pathophysiology of depression and its response to treatment 
(Haroon et al., 2018, Miller and Raison, 2016). Recent research has confirmed that hsCRP is a 
clinically valuable inflammatory marker, both peripheral and central, and can serve as a proxy for 
cytokines and other inflammatory mediators, which are more difficult to measure in the clinic 
(Felger et al., 2018, Miller et al., 2017). The CRP analysis has been described in detail in 
(Chamberlain et al., 2019) but briefly, the blood samples were collected in clot activator containing 
tubes for measurements of hsCRP. The samples were allowed to coagulate for 30-60 minutes then 
centrifuged at 1600 Relative Centrifugal Force (RCF) for 15 mins. The serum samples were 
separated and transported to a central laboratory (Q2 Solutions) where analysed on the day of 
receipt. Samples were exposed to anti-CRP-antibodies on latex particles, and the increase in light 
absorption due to complex formation was used to quantify hsCRP levels, using Turbidimetry on 
Beckman Coulter AU analyzers. Inter and intra-assay co-efficient of variations were <10%. The 
Clinical Reporting Range (CRR) for the hsCRP assay was 0.2 – 9,999.9 mg/L. 
2.4 Salivary Cortisol Measurements 
For cortisol measurements, salivary sampling has been the preferred method over blood sampling 





stress-free way to collect samples. A high correlation between plasma and salivary cortisol has been 
reported in studies investigating HPA axis function indicating that salivary cortisol measurements 
are a reliable marker of HPA axis assessment (Petrowski et al., 2013). Saliva samples were collected 
from participants according to our previously published procedure (Mondelli et al., 2010, Nikkheslat 
et al., 2015). Using salivette sampling devices (Sarstedt, Leicester, UK), the self-collection of 
samples was carried out at home at 6 time points throughout the day; at awakening, 15, 30 and 60 
minutes after awakening, at 12pm and at 8pm. Individuals who described problems during sample 
collection in the self-recorded questionnaire provided, or who did not respect the time-intervals 
required, were removed from the analysis. The current study includes those participants who 
completed saliva sample collections accurately and provided adequate amount of sample for 
measurements of cortisol. Salivary cortisol levels were measured using a commercially available 
high sensitivity salivary cortisol enzyme immunoassay kit (Salimetrics). SoftMax Pro 4.8 software 
was used to calculate the cortisol values, following a 4-parameter fit. The analytical sensitivity was 
set to 0.19 nmol/l. Inter and intra-assay co-efficient of variations ranged 8-10% and 6-10%, 
respectively. To investigate the activity and responsiveness of the HPA axis, we first compared the 
mean values at the various time points of salivary cortisol collection; and secondly, we calculated 
the area under the curve with respect to the increase (AUCi) for the cortisol awakening response 
using the 4 time points of 0, 15, 30, and 60 minutes after awakening; and the area under the curve 
with respect to the ground (AUCg) for the diurnal cortisol using the 3 main points over the whole 
day: awakening, noon 12 pm and 8pm. AUCg indicates the total amount of cortisol produced thus 
represents the HPA axis overall activity during the day. AUCi measures the variation (either positive 
or negative) in cortisol concentration thus signifies the HPA axis reactivity and response to the stress 
of awakening. The formulas for the calculations of the AUC were derived from the trapezoidal 





Glucocorticoid resistance was defined as coexistence of increased cortisol production and elevated 
hsCRP levels as a clinical biomarker of inflammation that indicates an impaired ability of cortisol 
to exert its anti-inflammatory effect. Therefore, individuals exhibiting the evidence for the presence 
of glucocorticoid resistance were characterised as those who had both high hsCRP>3 mg/L, which 
is indicative of an increased inflammation based on widely accepted cut-off points (Pearson et al., 
2003) and high diurnal cortisol levels, AUCg>50 nmol/L considering overall sample median. 
Subjects with the hsCRP values more than 10 mg/L representing the presence of acute inflammation 
were excluded from the analysis. 
2.5  Data Analysis 
All statistical analyses were performed using SPSS software version 24.0. All data were tested for 
suitability for parametric or non-parametric analysis. For comparisons of the four study groups, 
including the three groups of MDD patients and the group of controls, we performed one-way 
ANOVA analysis or Kruskal-Wallis test, where the data violated parametric assumptions confirmed 
by Shapiro-Wilk test. Tukey’s HSD test was used for post-hoc analysis for the pairwise group 
differences. Cohen’s d was reported for the effect size of hsCRP, CTQ and cortisol in each clinical 
group compared to healthy controls. Dichotomous variables including gender and glucocorticoid 
resistance were compared using Chi-square test. Correlations were assessed using Pearson’s product 
moment correlation. Mediation analysis was performed using the PROCESS macro. Linear 
Regression was carried out to investigate the association between childhood trauma and diurnal 
cortisol in both glucocorticoid resistance and non-resistance groups. A two-way ANOVA with 
repeated measures was used to determine the differences in salivary cortisol at different time points 
of the awakening response and during the day among the four groups. General linear model 





of covariates including BMI, age and gender on the outcomes. The p-values of <0.05 were 
considered as significant.  
3. RESULTS 
3.1 Sample Characteristics  
A total of 218 participants who provided saliva samples for cortisol measurements were included in 
this study. The sociodemographic and clinical characteristics of the study sample is presented in 
Table 1. Treatment responder, treatment non-responder and untreated depressed patients and 
controls showed similar age range (One-way ANOVA, F=1.05, p>0.05) and distribution of gender 
among the groups (Chi-square, χ2 =0.15, p>0.05). HAM-D scores were significantly different 
between each group compared with other groups, as confirmed by the pairwise post hoc analysis 
(Table 1) (One-way ANOVA, F=642.01, p<0.001). BDI-II was positively correlated with the HAM-
D17 (Pearson, r=0.757, p<0.0001). Overall, patients and controls differed significantly on their BMI 
(One-way ANOVA, F=2.96, p<0.05); however, running the post hoc analysis, the difference was 
only found between treatment responders and controls (p=0.047). Compared with healthy adults, 
depressed groups exhibited an increased level of inflammation as indicated by CRP marker (Table 
1) (One-way ANOVA, F=3.9, p<0.01). Patients also appeared to have experienced greater 
childhood trauma when each group was compared with controls (Table 1) (One-way ANOVA, 
F=12.62, p<0.001). 
TABLE 1. 
3.2 Childhood Trauma, Depression and Antidepressant Response  
Depressed individuals had significantly higher exposure to childhood trauma when compared with 





patients was compared with controls (Table 1). Comparing the two groups of patients under 
medication, treatment non-responder depressed patients revealed significantly higher CTQ total 
scores than treatment responders (U=1261.00, z=-2.259, p=0.024). Examining the potential 
mediating role of cortisol and hsCRP on the association between childhood trauma and adulthood 
depressive symptoms in treatment non-responder depressed patients indicated that the association 
was not mediated by the effect of cortisol (Direct effect of CTQ on BDI-II: B= 0.285, p = 0.0038 
and indirect effect via AUCg: p>0.05, CI -0.294, 0.014; direct effect of CTQ on AUCg: B= 0.0007, 
p = 0.998, and AUCg on BDI-II: B= -0.024, p = 0.423) or hsCRP (Direct effect of CTQ on BDI-II: 
B= 0.204, p = 0.0048 and indirect effect via hsCRP: p>0.05, CI -0.031, 0.026; direct effect of CTQ 
on hsCRP: B= 0.012, p = 0.459, and hsCRP on BDI-II: B= 0.398, p = 0.417) in these patients. 
3.3 Cortisol Production and Glucocorticoid Resistance  
The repeated measures ANOVA comparing the salivary cortisol at different time points among the 
groups showed no significant differences in the levels of cortisol at each time point between three 
groups of patients with depression (treatment responder, treatment non-responder and untreated 
patients) and controls, for both the first hour post awakening (Figure 1a) (Two-way ANOVA for 
the between-group effect, F(3,3)=0.793, p=0.50), and during the day (Figure 1b) (Two-way 
ANOVA for the between-group effect, F(3,2)=0.137, p=0.94). The results from calculating the 
AUCi (nmol.min/L) for the cortisol awakening response (Figure 1a) by measuring the variation 
(either positive or negative) in cortisol concentration revealed no differences in the HPA axis 
reactivity and response to the stress of awakening among the groups (Kruskal-Wallis, H=2.83, 
p=0.42) (Table 1). 
The AUCg for the diurnal cortisol (nmol.hr/L) (Figure 1b), indicative of the HPA axis overall 
activity by measuring the total amount of cortisol concentrations, was significantly different among 





difference between untreated depressed and treatment responder (U=630.00, z=-2.104, p=0.035, ES 
Cohen’s d=0.28) and between untreated depressed and treatment non-responder patients 
(U=1192.50, z=-2.451, p=0.014, ES Cohen’s d=0.2) (Table 1). Indeed, combining the two groups 
of patients who were on medication (both treatment responder and treatment non-responder) showed 
significantly lower diurnal cortisol production when compared with untreated depressed individuals 
(U=1822.50, z=-2.595, p=0.009). 
FIGURE 1 
Investigating the presence of glucocorticoid resistance, MDD patients showed higher prevalence of 
glucocorticoid resistance as compared with healthy adults (Chi-square, χ2=3.726, p=0.05). Further 
analysis revealed that depressed patients who were untreated had significantly higher proportion of 
individuals (26.8%) with glucocorticoid resistance (diurnal cortisol secretion above median and 
hsCRP>3 mg/L), than both treatment responder (11.9%) and treatment non-responder patients 
(6.3%), as well as controls (3.6%) (Chi-square, χ2=15.948, p=0.001) (Figure 2).  
FIGURE 2 
3.4 Association of Childhood Trauma with Cortisol and Glucocorticoid Resistance  
The severity of childhood trauma was not found to be associated with higher cortisol levels in 
depressed patients (p>0.05). However, in individuals with glucocorticoid resistance, childhood 
trauma was positively associated with greater diurnal cortisol output in adulthood (F=34.775, 







3.5 Covariate Analysis 
The effect of BMI as a confounder has been analysed on serum hsCRP, cortisol awakening response, 
diurnal salivary cortisol and the statistically significant results remained unchanged. The regression 
model has been also controlled for age, gender and BMI and the outcome remained unchanged. 
4. Discussion 
Our results show that depressed individuals, regardless of treatment response, had more experience 
of childhood trauma than healthy subjects. When considering the response to antidepressant 
medications, treatment non-responder patients had higher exposure to childhood trauma compared 
with responders. We did not find any specific HPA axis activity abnormality to be associated with 
non-response to the treatment. However, depressed patients who were on antidepressant medication 
showed lower total diurnal cortisol production compared with untreated patients. In addition, we 
found that the untreated group had higher proportion of individuals presenting with glucocorticoid 
resistance than medicated depressed patients and controls. Severity of childhood trauma was 
associated with increased diurnal cortisol levels only in individuals with glucocorticoid resistance.  
Cortisol is the primary end-product and the main peripheral marker of the HPA axis. Studies reveal 
mixed results when looking at the link between depression and the HPA axis as a principal 
endocrinological stress response system, with most findings suggesting the presence of HPA axis 
hyperactivation characterised by increased cortisol concentrations in almost half of MDD patients 
(Pariante 2017, Perrin et al., 2019, Herbert, 2013, Vreeburg et al., 2009). However, a systematic 
review and meta-analysis detected only a small difference in salivary cortisol levels between 
depressed patients and controls, and recommended the interpretation of results with caution due to 
a substantial overlap between values in the two groups, presence of random errors and bias, and 





degree of hypercortisolemia in depression may vary considerably depending on the type of 
depression and the age of patients included in the studies. The authors concluded that greater cortisol 
differences between depressed and non-depressed were mostly reported in older patients and also 
more in hospitalised individuals than outpatients (Stetler and Miller, 2011). These outcomes may 
explain no differences in cortisol awakening response and diurnal cortisol levels among the groups 
(Figure 1) of our current study, which was mainly focussing on a population of younger outpatient 
adults. These findings further suggest the HPA axis abnormalities may be more pronounced in 
specific groups of patients or may reflect more severe depressive states (hospitalized patients).  
The investigation on the association between antidepressant treatment and HPA axis activity by 
means of measuring AUCg for the diurnal cortisol output revealed lower cortisol levels in medicated 
depressed patients, both treatment responder and treatment non-responder, than those who were 
untreated. It appears that antidepressant medications, rather than depression status and regardless to 
the responsiveness, influence cortisol production in patients with depression. A recent meta-analysis 
assessed HPA axis functioning as predictor of depressive response and reported no differences in 
cortisol secretion between treatment responders and non-responders. Following the meta-regression 
analysis, the study revealed that compared with responders, the hypercortisolemia in non-responders 
were demonstrated only in those studies with no report on sample handling, no account for 
controlling for age, and excluding comorbidities (Fischer et al., 2017). While altered HPA axis alone 
may not be a robust marker for predicting treatment response, the findings supporting the effect of 
antidepressants in normalizing HPA axis dysregulation in depression cannot be overlooked 
(Pariante, 2017, Pariante and Lightman, 2008). Indeed, it has been evident that antidepressants, 
apart from their classic mechanism of action on the neurotransmitter system, have a distinct role in 
normalising HPA axis abnormalities by directly enhancing GR function and expression, thus 
promoting cortisol-mediated negative feedback regulation of the axis (Anacker et al., 2011a, 





glucocorticoid molecular pathways in various target tissues provides also other putative therapeutic 
related effects for example, by increasing hippocampal neurogenesis and reducing peripheral 
inflammation (Anacker et al., 2011b, Anacker et al., 2013, Carvalho et al., 2010). 
Our results revealed that depressed individuals were more likely to exhibit evidence of 
glucocorticoid resistance (coexistence of high cortisol and high hsCRP), and that untreated patients 
specifically had greater proportion of individuals presenting glucocorticoid resistance than 
medicated depressed patients and controls (Figure 2). Immune activation and inflammation have 
been consistently reported in depressed patients (Dowlati et al., 2010, Haapakoski et al., 2015, 
Huang et al., 2019, Valkanova et al., 2013). Regulation of inflammatory response is one of the key 
roles of glucocorticoids. The notion of glucocorticoid resistance in relation to inflammation has 
been studied extensively over the last two decades (Pariante 2017). Insights into molecular 
mechanisms underlying inflammatory dysregulation in depression disclosed a bidirectional 
association between inflammation and GR. Prolonged inflammation and activated cytokine-
signalling pathway interact with GR-signalling pathway leading to a decrease in GR sensitivity. A 
dysfunctional GR in turn shows an impaired responsiveness to cortisol and a reduced ability to 
perform anti-inflammatory action (Pace et al., 2007, Zunszain et al., 2011). Interestingly, it has been 
demonstrated that some antidepressants are able to improve GR function (Carvalho et al., 2010, 
Carvalho and Pariante, 2008, Pariante et al., 1997) and reverse glucocorticoid resistance (Pariante 
et al., 2012, Pariante et al., 2004). The findings, which support our result showing less prevalence 
of glucocorticoid resistance in medicated depressed groups, both treatment responder and treatment 
non-responder, suggest that antidepressant drugs, regardless of whether depressive symptoms 






Studies on treatment resistance depression also demonstrated elevated inflammatory response in the 
context of HPA axis hyperactivation and hypercortisolemia in severely depressed non-responder 
inpatients (Carvalho et al., 2008). The presence of glucocorticoid resistance was further confirmed 
on the same group of patients by in vitro evaluation of GR on their peripheral blood mononuclear 
cells that were unable to respond to synthetic glucocorticoid, dexamethasone, during immune 
challenge by bacterial lipopolysaccharide (Carvalho et al., 2010). Following the evidence 
suggesting the association of inflammation with depression and lack of clinical therapeutic benefit 
of antidepressants (Carvalho et al., 2013), recent research is focusing on targeting inflammation and 
use of anti-inflammatory medications in treatment of depression for those subgroups of patients who 
may require alternative or adjuvant therapeutic strategies (Husain et al., 2017, Kopschina Feltes et 
al., 2017, Miller and Raison, 2016). In our study, although the treatment non-responder group 
exhibit elevated inflammation and presence of glucocorticoid resistance in a subset of patients, we 
have not found significantly higher levels of hsCRP, cortisol and GR resistance compared with 
treatment responders; this finding would suggest involvement of other pathophysiological 
mechanisms and aetiological factors associated with their response to treatment, that is important to 
take into account, considering the heterogeneous nature of MDD. 
Childhood maltreatment as one of the most potent risk factors for development of depression 
adversely affects the course of illness and response to the antidepressant treatment (Kaplan and 
Klinetob, 2000, Williams et al., 2016). A meta-analysis looking at both epidemiological and clinical 
studies revealed that childhood maltreatment follows a greater risk of developing both recurrent and 
persistent depressive episodes in depressed adults and with poorer treatment outcome compared 
with depressed individuals without a history of childhood maltreatment (Nanni et al., 2012). Testing 
the hypothesis on the association between childhood trauma, depression and treatment response in 
line with mounting evidence documented up to date, the current study population of depressed 





When the response to antidepressant medications was considered, treatment non-responder 
individuals had indeed higher exposure to childhood trauma than treatment responders. In addition, 
the association between childhood trauma and adulthood depressive symptoms in treatment non-
responder patients was not found to be mediated by the effect of cortisol or hsCRP. These findings 
highlight the importance of early preventive and therapeutic interventions as well as enquiring 
information about childhood trauma as a routine clinical assessment of depression in order to 
identify individuals at higher risk of poor response to treatment. However, establishing alternative 
and more effective treatment options requires comprehensive understanding of the specific 
physiological phenotype and targeting those responsible biological abnormalities in this depressed 
group. It is important to note that not all individuals who are exposed to trauma in their childhood 
would develop depression later in life and some even demonstrate resilience to depression when 
exposed to additional stressors throughout life; this suggests the presence of opposite biological 
responses across different individuals probably mediated by genetic and epigenetic factors (Heim 
et al., 2009, Monroe and Reid, 2008). 
Recently, more research has attempted to identify the pathophysiological mechanisms underlying 
development of depression triggered by early life stress and to establish the existence of biologically 
distinguishable subtypes of depression associated with childhood trauma and to predict individuals 
who would be responsive to treatment (Harkness et al., 2011, Heim et al., 2008, Lu et al., 2016). 
Indeed, early exposure to life stress has been linked to neuroendocrine and neuroimmune changes 
including alterations in HPA axis activity (Harkness et al., 2011, Lu et al., 2016), increased cortisol 
reactivity and pro-inflammatory state in adulthood (Baumeister et al., 2016, Danese et al., 2007). In 
our attempt to investigate HPA axis function and inflammation as underlying physiological 
mechanisms linking childhood trauma with depression and treatment response, we have found that 
(Table 2) the severity of childhood trauma was associated with higher cortisol levels only in 





or the overall depressed subjects. These findings indicate different neuroendocrine and 
neuroimmune responses to childhood trauma in individuals with depression. Based on evidence 
suggesting that neuroendocrine and neuroimmune alterations secondary to childhood trauma 
significantly increase vulnerability to the lifetime stress reactivity and subsequent risk for the onset 
of depressive episodes (Heim et al., 2008, Nemeroff and Binder, 2014), our findings suggest that 
development of depression in adults exposed to early life trauma, is associated with increased HPA 
axis activation in the context of glucocorticoid resistance. Coexistence of hypercortisolemia and 
inflammatory biomarkers represents insufficient glucocorticoid signalling in this subgroup of 
patients probably due to impairment in GR functioning. Direct evaluation of GR functional 
properties has been extensively studied in depression and in relation to antidepressants treatment. 
With regards to early life stress and future development of depression, there is evidence from genetic 
studies on the association of polymorphisms in genes regulating the HPA axis and GR with 
depression and childhood trauma (Bet et al., 2009, Heim and Binder, 2012, Roy et al., 2010). 
Epigenetic studies also have shown a decrease hippocampal GR expression in animal models 
(Meaney and Szyf, 2005) and in abused suicide victims (McGowan et al., 2009). 
To our knowledge this study is the first to investigate measures of HPA axis and inflammation in 
the context of glucocorticoid resistance in relation to childhood trauma, depression and treatment 
response in the same population. The large sample size confirms validity of findings from other 
smaller studies, which also investigated only some of these pathophysiological disturbances. 
Despite a comprehensive assessment, there are few limitations need to be mentioned. Firstly, 
patients were not stratified according to depression subtypes. Based on the evidence atypical 
depression may not be associated with HPA axis hyperactivity and hypercortisolemia, which are 
observed in melancholic depressive subtype (Juruena et al., 2018). In addition, since this is a cross-
sectional study, future longitudinal studies are needed to confirm our findings. Finally, we only 





evidence for glucocorticoid resistance, and therefore, an evaluation of GR function both by in vivo 
assessment on the HPA axis (dexamethasone suppression test) and in vitro measurements on blood 
immune cells (dexamethasone-inhibition of LPS-induced cytokine levels) in future studies are 
needed to confirm an impairment of the GR-mediated glucocorticoid resistance. It would be also 
valuable for future studies to evaluate other inflammatory markers which have been associated with 
both childhood trauma and depression, as well to investigate potential differential effects of 
antidepressant on immune processes. 
Conclusion  
Although we found a link between childhood trauma and non-response to the antidepressant 
treatment in our depressed patients, we did not find specific evidence of HPA axis hyperactivity or 
glucocorticoid resistance in our treatment non-responder patients. However, our results showed that 
untreated depressed patients had increased diurnal cortisol and a higher prevalence of glucocorticoid 
resistance when compared with depressed patients on antidepressant medication. Our study shows 
that severity of childhood trauma contributes to increased HPA axis hyperactivity specifically in 
patients who present glucocorticoid resistance. These findings support a role of glucocorticoid 
resistance in amplifying the effects of childhood trauma in activating the HPA axis and suggest 
glucocorticoid resistance as a target for the development of personalised treatment for a subgroup 
of depressed patients with a history of childhood trauma rather than for all patients with resistance 
to antidepressant treatment. Future studies should investigate alternative or adjuvant treatment 
strategies that may improve glucocorticoid signalling in affected individuals and thereby reduce 
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